Boston-based Proteostasis Therapeutics Inc. and Astellas Pharma Inc. will initially work together to discover, screen and conduct preclinical research on drugs that modulate unfolded protein response (UPR). The primary focus will be on one (unidentified) genetic disease, but the partners will also look at other possible indications that are linked to modulation of UPR pathways.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?